Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Carbimazole→

Carbimazole Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
22232-54-8
Molecular formula
C7H10N2O2S
Molecular weight
186.23 g/mol
Drug class
Thionamide antithyroid agentprodrug of thiamazole (methimazole)
Mechanism of action
Carbimazole is rapidly converted to thiamazole, which inhibits thyroid peroxidase-mediated iodide organification and coupling of iodotyrosine residues, suppressing thyroid-hormone synthesis.
Indications / reported uses
  • Treatment of hyperthyroidism
  • Preparation for thyroidectomy in hyperthyroidism
  • Treatment before and after radioiodine therapy; indication and regimen depend on product information

Sources: UK SmPC — Carbimazole 10 mg tablets · UK SmPC — Carbimazole 5 mg tablets · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Carbimazole Environmental Risk Assessment (ERA) (the Carbimazole ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.